publication date: May. 10, 2019

Clinical Roundup BMS phase III study didn’t meet primary endpoint of OS with Opdivo + radiation in glioblastoma multiforme

Bristol-Myers Squibb Co. said the phase III CheckMate-498 trial evaluating Opdivo (nivolumab) plus radiation vs. temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma multiforme did not meet its primary endpoint of overall survival at final analysis.

The safety profile of Opdivo was consistent with previously reported studies in solid tumors. The company will complete a full evaluation of the data from CheckMate-498 and work with investigators on the future presentation and publication of the results.

“While we are disappointed the CheckMate-498 trial did not meet its primary endpoint, GBM is a notoriously aggressive cancer,” said Fouad Namouni, head of the oncology development, Bristol-Myers Squibb. “We are grateful to all those who participated in this trial and remain committed to researching the potential of immunotherapy to address the important unmet medical need of patients who suffer from this devastating disease.”

Opdivo is also being studied in patients with newly diagnosed MGMT-methylated GBM in the phase III CheckMate-548 (NCT02667587) study, in which Opdivo is added to the current standard of care, radiation plus temozolomide.

CheckMate-498 (NCT02617589) is a phase III randomized, multi-center study evaluating Opdivo and radiation versus temozolomide and radiation in patients with newly diagnosed … Continue reading BMS phase III study didn’t meet primary endpoint of OS with Opdivo + radiation in glioblastoma multiforme

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.